HC Wainwright Issues Negative Estimate for AXSM Earnings

Key Points

• HC Wainwright has cut its Q2 2026 earnings per share estimate for Axsome Therapeutics from $0.82 to $0.64, while maintaining a "Buy" rating with a $180.00 price target.
• Despite the earnings estimate reduction, several analysts, including Royal Bank of Canada and Bank of America, have raised their price targets for the stock, indicating continued investor interest.
• Axsome Therapeutics reported a quarterly loss of ($0.92) per share, which was better than analysts' expectations, and generated revenue of $150.04 million, surpassing estimates of $140.02 million.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - HC Wainwright reduced their Q2 2026 earnings per share estimates for Axsome Therapeutics in a research note issued on Wednesday, August 6th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.64 per share for the quarter, down from their prior forecast of $0.82. HC Wainwright currently has a "Buy" rating and a $180.00 price target on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics' Q3 2026 earnings at $1.51 EPS and Q4 2026 earnings at $2.03 EPS.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.08. The firm had revenue of $150.04 million during the quarter, compared to analysts' expectations of $140.02 million. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.

A number of other analysts have also recently weighed in on the company. Oppenheimer started coverage on Axsome Therapeutics in a research report on Tuesday, June 3rd. They set an "outperform" rating and a $185.00 price objective for the company. Cantor Fitzgerald upgraded Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Wells Fargo & Company restated an "overweight" rating and issued a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a report on Tuesday, May 6th. Needham & Company LLC reissued a "buy" rating and set a $150.00 price target on shares of Axsome Therapeutics in a research report on Monday, August 4th. Finally, Morgan Stanley initiated coverage on shares of Axsome Therapeutics in a research report on Thursday, July 3rd. They set an "overweight" rating and a $190.00 price target for the company. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $178.00.

Axsome Therapeutics Trading Down 1.5%

NASDAQ AXSM traded down $1.57 on Thursday, reaching $103.24. 129,081 shares of the company were exchanged, compared to its average volume of 784,026. The business's fifty day moving average price is $105.86 and its 200 day moving average price is $110.90. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. Axsome Therapeutics has a fifty-two week low of $75.56 and a fifty-two week high of $139.13. The stock has a market capitalization of $5.15 billion, a P/E ratio of -20.36 and a beta of 0.51.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark Coleman sold 3,750 shares of Axsome Therapeutics stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total transaction of $395,512.50. Following the completion of the sale, the director owned 50,387 shares of the company's stock, valued at $5,314,316.89. The trade was a 6.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Mark L. Jacobson sold 25,000 shares of Axsome Therapeutics stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $110.44, for a total value of $2,761,000.00. Following the completion of the transaction, the chief operating officer owned 5,783 shares in the company, valued at approximately $638,674.52. This represents a 81.21% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 93,437 shares of company stock valued at $9,834,215. 22.40% of the stock is owned by insiders.

Institutional Trading of Axsome Therapeutics

A number of hedge funds have recently made changes to their positions in AXSM. Caitong International Asset Management Co. Ltd bought a new position in Axsome Therapeutics in the 1st quarter valued at approximately $25,000. NBC Securities Inc. purchased a new stake in Axsome Therapeutics during the 1st quarter valued at $31,000. Quantbot Technologies LP purchased a new stake in shares of Axsome Therapeutics in the 1st quarter worth $31,000. AlphaQuest LLC purchased a new stake in shares of Axsome Therapeutics in the 1st quarter worth $38,000. Finally, Neo Ivy Capital Management purchased a new stake in shares of Axsome Therapeutics in the 1st quarter worth $41,000. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.